









|
| @ŠÖ“Œ˜A‡ŽY‰È•wl‰ÈŠw‰ï‰ïŽ ƒIƒ“ƒ‰ƒCƒ“ƒWƒƒ[ƒiƒ‹ |
<< Šw‰ïނ֖߂é
<< ‘O‚̃y[ƒW‚Ö–ß‚é
‘æ91‰ñŠwpW‰ïi•½¬8”N6ŒŽ16“új
yˆê”ʉ‰‘èz
—‘‘ƒtransitional cell carcinoma‚Ì3Ç—á
…Œû@„—Y, ‹gì@—T”V, ‚]@Œ’‘¾˜Y, ”Ñ“c@‘ì, ¬—Ñ@_ˆê, ‰¶“c@‹MŽu, ‰ªˆä@’, •’J@—Y“ñ(1), ŽR“à@’¼Žq, Ž“‡@Œ’Ži, â–{@–s•F(2)
(1)“Œ‹ž‘åŠwˆãŠw•”ŽY‰È•wl‰È, (2)“¯•a—Šw‹³Žº
“ú–{ŽY‰È•wl‰ÈŠw‰ïŠÖ“Œ˜A‡’n•û•”‰ï‰ï•ñ, 33(2)
167-167, 1996
|